MSFT
Microsoft Corporation
MSFT's fundamentals are strong and it looks cheap: trading at 27x earnings, below its usual 34x. Analysts expect strong earnings growth.
SURG
SurgePays, Inc.
There isn't enough reported data to score SURG yet.
MSFT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Strong |
MSFT's revenue, profitability, cash flow and balance sheet are all currently healthy.
SURG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Strong |
SURG's revenue and balance sheet are currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow.
MSFT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $523 | — |
| Cheap | 27x | $525 | +0.4% |
| Current | 27x | $523 | — |
| Fair | 34x | $652 | +25% |
| Expensive | 37x | $711 | +36% |
Historical ranges are pointers, not guarantees.
MSFT's PE is in its cheap range at 27x. If earnings grow as analysts expect, today's price would be 25x next year's earnings.
SURG PE Valuation
SURG has no meaningful PE right now: it lost money over the past year.
MSFT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Moderate | |
| High |
Analysts expect strong earnings and revenue growth for MSFT, with profitability holding steady.
SURG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SURG's losses to shrink, with revenue holding steady.
MSFT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $20.79 | +8.6% |
| Q3 2026 | $19.15 | +36% |
| Q2 2026 | $17.95 | +32% |
| Q1 2026 | $16.80 | +30% |
| Q4 2025 | $15.99 | +29% |
| Q3 2025 | $14.06 | +16% |
| Q2 2025 | $13.64 | +16% |
| Q1 2025 | $12.93 | +12% |
| Q4 2024 | $12.41 | +12% |
MSFT has the edge over SURG on earnings quality, reporting a profit while its opponent remains loss making.
SURG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.52 | +$1.02 |
| Q1 2026 | -$1.93 | +$0.91 |
| Q4 2025 | -$1.80 | +$0.59 |
| Q3 2025 | -$2.19 | -$1.05 |
| Q2 2025 | -$2.54 | -3275% |
| Q1 2025 | -$2.84 | -349% |
| Q4 2024 | -$2.39 | -273% |
| Q3 2024 | -$1.14 | -179% |
SURG is still losing money, but far less than before: $1.52 per share over the past year, against $5.50 at its worst in early 2021.
MSFT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $92.3B | +19% |
| Q2 2026 | $90B | +18% |
| Q1 2026 | $82.9B | +18% |
| Q4 2025 | $81.3B | +17% |
| Q3 2025 | $77.7B | +18% |
| Q2 2025 | $76.4B | +18% |
| Q1 2025 | $70.1B | +13% |
| Q4 2024 | $69.6B | +12% |
MSFT has the edge over SURG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 50% | +0.9 points |
| Q2 2026 | 45% | +0.2 points |
| Q1 2026 | 46% | +0.7 points |
| Q4 2025 | 47% | +1.6 points |
| Q3 2025 | 49% | +2.3 points |
| Q2 2025 | 45% | +1.8 points |
| Q1 2025 | 46% | +1.1 points |
| Q4 2024 | 45% | +1.9 points |
MSFT has the edge over SURG on profitability, with a higher operating margin.
SURG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $16.2M | +41% |
| Q1 2026 | $16M | +51% |
| Q4 2025 | $16.2M | +69% |
| Q3 2025 | $18.7M | +292% |
| Q2 2025 | $11.5M | -24% |
| Q1 2025 | $10.6M | -66% |
| Q4 2024 | $9.6M | -70% |
| Q3 2024 | $4.8M | -86% |
SURG's revenue is recovering but still below its 2022 peak: $16M last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 21% | +80 points |
| Q1 2026 | -70% | +1.6 points |
| Q4 2025 | -79% | +113 points |
| Q3 2025 | -37% | +262 points |
| Q2 2025 | -59% | +13 points |
| Q1 2025 | -72% | -77 points |
| Q4 2024 | -192% | -194 points |
| Q3 2024 | -299% | -320 points |
SURG's operating margin was 21% last quarter, up 80 points from the same quarter a year ago, near the top of its range since 2019.
MSFT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $18.6B | -27% |
| Q2 2026 | $19.6B | -23% |
| Q1 2026 | $15.8B | -22% |
| Q4 2025 | $5.9B | -9.3% |
| Q3 2025 | $25.7B | +33% |
| Q2 2025 | $25.6B | +9.6% |
| Q1 2025 | $20.3B | -3.2% |
| Q4 2024 | $6.5B | -29% |
MSFT has the stronger cash trend. Its trailing FCF is down 7.4% versus its history, compared with SURG at down 63%.
SURG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.6M | +$3.5M |
| Q1 2026 | -$4.6M | +$2.4M |
| Q3 2025 | -$4.6M | +$8.7M |
| Q2 2025 | -$6.1M | -$2M |
| Q1 2025 | -$7M | -272% |
| Q4 2022 | $4.7M | +$12.9M |
| Q3 2022 | -$801.2K | +$1.5M |
| Q2 2022 | $175.5K | +$1.6M |
SURG has burned cash in almost every quarter: −$18M over the past year, against −$20M the year before.
MSFT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -7M shares |
| 1 year | -0.3% | -20M shares |
| 3 years | -0.2% | -16M shares |
| 5 years | -1.6% | -121M shares |
| Available history | -3.2% | -245M shares |
MSFT has the edge over SURG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.4B |
| Q2 2026 | $4.6B |
| Q1 2026 | $4.6B |
| Q4 2025 | $7.4B |
| Q3 2025 | $5.7B |
| Q2 2025 | $4.5B |
| Q1 2025 | $4.8B |
| Q4 2024 | $5B |
MSFT spent $21B buying back its own shares over the past year, up 5.2% from the year before.
SURG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.4% | +2.2M shares |
| 1 year | +29% | +5.9M shares |
| 3 years | +109% | +13.5M shares |
| 5 years | +1122% | +23.8M shares |
SURG has 26M diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
MSFT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | 0.1x | Very low |
MSFT's net debt is less than a year of its operating earnings (EBITDA).
SURG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -2.2x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -0.3x | Net Cash |
| Q2 2023 | 0.0x | Very low |
| Q1 2023 | -0.3x | Net Cash |
| Q4 2022 | 0.4x | Very low |
SURG has more cash than debt.
MSFT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.1 | Neutral |
| Stochastic | 68.0 | Neutral |
MSFT's weekly RSI is 62 (neutral) and its Stochastic is 68 (neutral).
SURG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.5 | Neutral |
| Stochastic | 13.7 | Oversold |
SURG's weekly RSI is 32 (neutral) and its Stochastic is 14 (oversold).
MSFT PE vs Technology Sector
| Metric | MSFT | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 28x | 2% below |
| PE % | 16 | 35 | 19 pts below |
MSFT is trading at 27x earnings, in line with the Technology sector's median of 28x.
SURG PE vs Technology Sector
| Metric | SURG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
SURG has no meaningful PE right now: it lost money over the past year.
MSFT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $524.7 | 0.3% below |
| 20 week MA | $484.8 | 7.9% above |
| 50 week MA | $446.9 | 17% above |
| 100 week MA | $453.8 | 15% above |
| 200 week MA | $411.5 | 27% above |
MSFT has the edge over SURG on trend strength, trading above more of its moving averages.
SURG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.14 | 0% above |
| 20 week MA | $0.21 | 33% below |
| 50 week MA | $0.65 | 78% below |
| 100 week MA | $1.50 | 91% below |
| 200 week MA | $3.02 | 95% below |
SURG is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
MSFT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $159.0 | $222.8 | +40% |
| 2021 | $222.8 | $334.7 | +50% |
| 2022 | $334.7 | $238.7 | -29% |
| 2023 | $238.7 | $376.0 | +58% |
| 2024 | $376.0 | $430.5 | +14% |
| 2025 | $430.5 | $487.7 | +13% |
| 2026 YTD | $487.7 | $523.0 | +7.2% |
MSFT has the edge over SURG on returns for 2026, with the stronger performance.
SURG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.8 | $6.00 | -59% |
| 2021 | $6.00 | $2.31 | -62% |
| 2022 | $2.31 | $6.29 | +172% |
| 2023 | $6.29 | $6.45 | +2.5% |
| 2024 | $6.45 | $1.83 | -72% |
| 2025 | $1.83 | $1.68 | -8.2% |
| 2026 YTD | $1.68 | $0.14 | -92% |
SURG's yearly returns have swung widely, from +172% in 2022 to −72% in 2024. It's down 92% so far in 2026.